ENSC
Ensysce BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
If Nasdaq accepts the plan and PF614-301 keeps advancing, the stock can still re-rate sharply because the current equity base is tiny and any clinical de-risking would matter disproportionately.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Cash and cash equivalents were only $745,482 at 2026-03-31, versus $4.31 million at 2025 year-end, and management says cash only funds operations into late Q2 2026 [#10-Q-2026-05-15].
Momentum
81
Value
41
Sentiment
33
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.18 · Bull $0.85 · Bear $0.05
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $25.23
Why
Momentum81 · Δ7d -
Value41 · Δ7d +0.1
Sentiment33 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
81
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
33
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 81.5 / Value 41.1 / Sentiment 33.4
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$4.11M
Beta
1.18
Shares Out
3.54M
P/E (TTM) · Derived
-0.1
P/S (TTM)
0.82
P/FCF (TTM) · Derived
-0.32
Rev YoY
-85.6%
EPS YoY
-228.7%
Gross Margin
-
Op Margin
-245.9%
Net Debt
-$3.2M
Current Ratio
1.27
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology